US20030181749A1 - Supercritical fluid extraction of vitreoretinal silicone tamponades - Google Patents
Supercritical fluid extraction of vitreoretinal silicone tamponades Download PDFInfo
- Publication number
- US20030181749A1 US20030181749A1 US10/165,834 US16583402A US2003181749A1 US 20030181749 A1 US20030181749 A1 US 20030181749A1 US 16583402 A US16583402 A US 16583402A US 2003181749 A1 US2003181749 A1 US 2003181749A1
- Authority
- US
- United States
- Prior art keywords
- carbon dioxide
- approximately
- fluid
- silicone oil
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229920001296 polysiloxane Polymers 0.000 title abstract description 22
- 238000000194 supercritical-fluid extraction Methods 0.000 title description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 103
- 229910002092 carbon dioxide Inorganic materials 0.000 claims abstract description 57
- 239000012530 fluid Substances 0.000 claims abstract description 54
- 239000001569 carbon dioxide Substances 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 44
- 229920002545 silicone oil Polymers 0.000 claims abstract description 34
- 238000000605 extraction Methods 0.000 claims abstract description 29
- 238000000746 purification Methods 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 32
- 125000004122 cyclic group Chemical group 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 3
- 239000003607 modifier Substances 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims 2
- 230000002207 retinal effect Effects 0.000 claims 1
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 claims 1
- -1 cyclic siloxanes Chemical class 0.000 abstract description 4
- 239000002904 solvent Substances 0.000 description 11
- 239000003921 oil Substances 0.000 description 5
- 210000001525 retina Anatomy 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 229910018503 SF6 Inorganic materials 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 239000003855 balanced salt solution Substances 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- WRQGPGZATPOHHX-UHFFFAOYSA-N ethyl 2-oxohexanoate Chemical compound CCCCC(=O)C(=O)OCC WRQGPGZATPOHHX-UHFFFAOYSA-N 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 1
- 229960000909 sulfur hexafluoride Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0834—Compounds having one or more O-Si linkage
- C07F7/0838—Compounds with one or more Si-O-Si sequences
- C07F7/0872—Preparation and treatment thereof
- C07F7/089—Treatments not covered by a preceding group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/20—Purification, separation
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
- C08G77/04—Polysiloxanes
- C08G77/32—Post-polymerisation treatment
- C08G77/34—Purification
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Definitions
- the present invention relates to a novel, highly effective method to purify vitreofluid silicone oils or fluids using supercritical fluid extraction. More particularly, the present invention relates to a method for purifying vitreofluid silicone oils or fluids that is contaminant-free and, in most cases, does not require the disposal of organic solvents.
- Ocular tamponades are vitreous substitutes that are used to reposition the retina of an eye in instances where a reattachment is not achievable by natural healing or by laser coagulation.
- the purpose of a vitreous substitute is to provide long-term tamponade of the retina, i.e., exhibit an ideal pressure (force/area) to position and maintain the retina in place.
- Current commercially used tamponades include perfluorocarbon-liquids, balanced salt solutions, silicone oil or fluid and gases, such as air, sulfur hexafluoride (SF 6 ) and perfluorocarbons (PFCs). Silicone oil or fluid is the preferred tamponade in cases of severe retina detachment, where the tamponade is used six months or longer.
- Silicone oil or fluid is prepared by a ring-opening polymerization of strained cyclic silicones.
- the final product consists of relatively high molecular weight silicone fluid and unreacted relatively low molecular weight cyclic siloxanes and oligomers.
- the unreacted relatively low molecular weight cyclics and oligomers are cytotoxic and have been implicated in an undesirable emulsification phenomenon that sometimes occurs in silicone-based fluids. Accordingly, the unreacted relatively low molecular weight cyclics and oligomers must be removed from the silicone fluid product to be useful as an ocular tamponade.
- the preferred current method of purifying relatively high molecular weight silicone oil, or silicone fluid involves the use of a lengthy solvent extraction process whereby the silicone fluid is slowly added to a non-solvent, such as acetone, and allowed to separate.
- a non-solvent such as acetone
- the unreacted low molecular weight cyclics and oligomers are soluble in the non-solvent or acetone phase.
- the unreacted low molecular weight cyclics and oligomers are thus removed with the non-solvent or acetone phase upon separation thereof from the high molecular weight silicone fluid.
- the non-solvent phase with the low molecular weight cyclics and oligomers becomes an undesirable waste product of the purification method and requires disposal.
- controls are necessary to ensure the final silicone oil or fluid product is free of non-solvent contamination.
- the present invention is an economical, highly effective process for the purification of relatively high molecular weight vitreofluid silicone oils or fluids using carbon dioxide supercritical fluid (SCF) extraction.
- a fluid with its temperature and pressure simultaneously higher than its critical temperature and pressure is in the supercritical state.
- SCF supercritical fluid
- carbon dioxide is a gas at ambient conditions. In a supercritical state, it is essentially a compressed, high density fluid.
- Carbon dioxide is relatively innocuous, economical, and non-reactive under most operating conditions.
- the density, solvent power or selectivity of a SCF is easily altered with relatively small changes in pressure or by addition of small amounts of an organic solvent. The change in carbon dioxide density with pressure at 35 degrees Celsius does not increase linearly with increasing pressure.
- Another object of the present invention is to provide a process for the purification of relatively high molecular weight silicone fluid that is economical.
- Another object of the present invention is to provide a process for the purification of relatively high molecular weight silicone fluid that is reproducible.
- Another object of the present invention is to provide a process for the purification of relatively high molecular weight silicone fluid that is contaminant-free.
- Another object of the present invention is to provide a process for the purification of relatively high molecular weight silicone fluid for use as an ocular tamponade.
- Still another object of the present invention is to provide a process for the purification of a relatively high molecular weight silicone fluid that lessens or eliminates the need for non-solvent waste disposal.
- a further object of the present invention is to eliminate low molecular weight silicone oligomers and cyclics from relatively high molecular weight silicone fluid in order to lessen or eliminate emulsification of the relatively high molecular weight silicone fluid in ocular tamponade uses.
- the present invention relates to a novel process for the purification of relatively high molecular weight silicone oil or fluid for use as an ocular tamponade.
- the purification process of the present invention is a novel, economical, highly effective, reproducible, contaminant-free process for removing relatively low molecular weight cyclics and oligomers from relatively high molecular weight silicone oil or fluid.
- the subject process utilizes supercritical carbon dioxide (scCO 2 ) fluid extraction to purify silicone fluid for use as an ocular tamponade.
- the supercritical carbon dioxide fluid has solvating powers comparable to those of organic solvents.
- the solvating power of the supercritical carbon dioxide fluid is adjustable through variations in pressure and temperature, or by adding modifiers to form a mixture as discussed in more detail below.
- suitable modifiers include but are not limited to methanol, isopropanol, acetonitrile and acetone.
- a 5,000 cps silicone oil tamponade was purified using supercritical carbon dioxide fluid extraction.
- the conditions of the supercritical carbon dioxide fluid extraction consisted of carbon dioxide at a pressure of approximately 3,000 pounds per square inch (psi), a temperature of approximately 55 degrees Celsius and a flow rate of approximately 52 gm per minute.
- the relatively low molecular weight cyclics and oligomers were removed from the silicone fluid to a level below size exclusion chromatography (SEC) detection limits. More particularly, SEC showed the removal of relatively low molecular weight cyclics and oligomers with no change in the silicone fluid peak height. Similar results were obtained by extracting with supercritical carbon dioxide fluid containing 10 percent acetone.
- Polydimethylsiloxane (21.01 gm) sample was loaded into a 0.7 inch tube. The loaded tube was then placed in a 3.0 inch cup. The 3.0 inch cup with the sample was placed into an extraction vessel and a lid with a 1 ⁇ 4 inch pipe attachment was placed on the extraction vessel. The lid was placed such that the 1 ⁇ 4 inch pipe attachment was inside the 0.7 inch tube.
- the extraction vessel was then pressurized to 140 bar with carbon dioxide using bottom to top flow. The extraction vessel temperature was approximately 55 degrees Celsius in an oil bath of approximately 102 degrees Celsius. A flow of 26 gm per minute carbon dioxide was begun in the extraction vessel from the top to the bottom. After one hour and 37 minutes, an increased flow rate of 52 gm per minute carbon dioxide was begun.
- Polydimethylsiloxane (21.01 gm) sample was loaded into a 0.7 inch tube. The loaded tube was then placed in a 3.0 inch cup. The 3.0 inch cup with the sample was then placed in an extraction vessel and a lid with a 1 ⁇ 4 inch pipe attachment was placed on the extraction vessel. The lid was placed such that the 1 ⁇ 4 inch pipe attachment was inside the 0.7 inch tube. The extraction vessel was then pressurized to 140 bar with carbon dioxide using bottom to top flow. The extraction vessel temperature was approximately 55 degrees Celsius in an oil bath of approximately 102 degrees Celsius. A flow of 6 gm per minute acetone and 20 gm per minute carbon dioxide was begun in the extraction vessel from the top to the bottom.
- Silicone oil or fluid ocular tamponades purified using the purification process of the present invention are used as customary in the field of ophthalmology.
- the silicone oil or fluid ocular tamponade purified in accordance with the process of the present invention is placed and maintained in the posterior segment of the eye for the desired period of time prior to the removal thereof.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Silicon Polymers (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Extraction Or Liquid Replacement (AREA)
Abstract
A process for the purification of a silicone oil or fluid using neat supercritical carbon dioxide or a supercritical carbon dioxide mixture extraction to produce vitreoretinal silicone tamponades. The subject process is an economical, highly effective, reproducible, contaminant-free method by which unreacted relatively low molecular weight cyclic siloxanes and oligomers are removed from relatively high molecular weight silicone oil or fluid.
Description
- Priority is hereby claimed in the present nonprovisional application to Provisional Application Serial No. 60/366,696 filed Mar. 21, 2002, in accordance with 37 CFR 1.78(a)(4).
- The present invention relates to a novel, highly effective method to purify vitreofluid silicone oils or fluids using supercritical fluid extraction. More particularly, the present invention relates to a method for purifying vitreofluid silicone oils or fluids that is contaminant-free and, in most cases, does not require the disposal of organic solvents.
- Ocular tamponades are vitreous substitutes that are used to reposition the retina of an eye in instances where a reattachment is not achievable by natural healing or by laser coagulation. The purpose of a vitreous substitute is to provide long-term tamponade of the retina, i.e., exhibit an ideal pressure (force/area) to position and maintain the retina in place. Current commercially used tamponades include perfluorocarbon-liquids, balanced salt solutions, silicone oil or fluid and gases, such as air, sulfur hexafluoride (SF6) and perfluorocarbons (PFCs). Silicone oil or fluid is the preferred tamponade in cases of severe retina detachment, where the tamponade is used six months or longer.
- Silicone oil or fluid is prepared by a ring-opening polymerization of strained cyclic silicones. The final product consists of relatively high molecular weight silicone fluid and unreacted relatively low molecular weight cyclic siloxanes and oligomers. The unreacted relatively low molecular weight cyclics and oligomers are cytotoxic and have been implicated in an undesirable emulsification phenomenon that sometimes occurs in silicone-based fluids. Accordingly, the unreacted relatively low molecular weight cyclics and oligomers must be removed from the silicone fluid product to be useful as an ocular tamponade. The preferred current method of purifying relatively high molecular weight silicone oil, or silicone fluid, involves the use of a lengthy solvent extraction process whereby the silicone fluid is slowly added to a non-solvent, such as acetone, and allowed to separate. The unreacted low molecular weight cyclics and oligomers are soluble in the non-solvent or acetone phase. The unreacted low molecular weight cyclics and oligomers are thus removed with the non-solvent or acetone phase upon separation thereof from the high molecular weight silicone fluid. Once separated, the non-solvent phase with the low molecular weight cyclics and oligomers becomes an undesirable waste product of the purification method and requires disposal. Likewise, following purification, controls are necessary to ensure the final silicone oil or fluid product is free of non-solvent contamination.
- Because of the noted shortcomings of the current, preferred method of silicone fluid purification to remove cytotoxic impurities therefrom, there is a need for a purification method that is effective, less time consuming, eliminates the potential for non-solvent residual contamination and lessens or eliminates non-solvent waste production.
- The present invention is an economical, highly effective process for the purification of relatively high molecular weight vitreofluid silicone oils or fluids using carbon dioxide supercritical fluid (SCF) extraction. A fluid with its temperature and pressure simultaneously higher than its critical temperature and pressure is in the supercritical state. The most ubiquitous SCF, carbon dioxide, is a gas at ambient conditions. In a supercritical state, it is essentially a compressed, high density fluid. Carbon dioxide is relatively innocuous, economical, and non-reactive under most operating conditions. The density, solvent power or selectivity of a SCF is easily altered with relatively small changes in pressure or by addition of small amounts of an organic solvent. The change in carbon dioxide density with pressure at 35 degrees Celsius does not increase linearly with increasing pressure. Small changes in pressure produce large changes in density when operating close to the critical point. For example, at 83 bar the compressibility of carbon dioxide is high. At 700 bar, the compressibility of carbon dioxide is low. The advantages of using carbon dioxide SCF for purification of vitreofluid silicone oils or fluids is that it is economical, reproducible, contaminant-free and in most cases does not require the disposal of non-solvent waste. Carbon dioxide SCF extraction in accordance with the present invention has solvating powers comparable to those of the non-solvents currently used in the purification of relatively high molecular weight silicone oil or fluid.
- Accordingly, it is an object of the present invention to provide a process for the purification of relatively high molecular weight silicone fluid.
- Another object of the present invention is to provide a process for the purification of relatively high molecular weight silicone fluid that is economical.
- Another object of the present invention is to provide a process for the purification of relatively high molecular weight silicone fluid that is reproducible.
- Another object of the present invention is to provide a process for the purification of relatively high molecular weight silicone fluid that is contaminant-free.
- Another object of the present invention is to provide a process for the purification of relatively high molecular weight silicone fluid for use as an ocular tamponade.
- Still another object of the present invention is to provide a process for the purification of a relatively high molecular weight silicone fluid that lessens or eliminates the need for non-solvent waste disposal.
- A further object of the present invention is to eliminate low molecular weight silicone oligomers and cyclics from relatively high molecular weight silicone fluid in order to lessen or eliminate emulsification of the relatively high molecular weight silicone fluid in ocular tamponade uses.
- These and other objectives and advantages of the present invention, some of which are specifically described and others that are not, will become apparent from the detailed description and claims that follow.
- The present invention relates to a novel process for the purification of relatively high molecular weight silicone oil or fluid for use as an ocular tamponade. The purification process of the present invention is a novel, economical, highly effective, reproducible, contaminant-free process for removing relatively low molecular weight cyclics and oligomers from relatively high molecular weight silicone oil or fluid. The subject process utilizes supercritical carbon dioxide (scCO2) fluid extraction to purify silicone fluid for use as an ocular tamponade. The supercritical carbon dioxide fluid has solvating powers comparable to those of organic solvents. Likewise, the solvating power of the supercritical carbon dioxide fluid is adjustable through variations in pressure and temperature, or by adding modifiers to form a mixture as discussed in more detail below. Examples of suitable modifiers include but are not limited to methanol, isopropanol, acetonitrile and acetone.
- Using the process of the present invention, a 5,000 cps silicone oil tamponade was purified using supercritical carbon dioxide fluid extraction. The conditions of the supercritical carbon dioxide fluid extraction consisted of carbon dioxide at a pressure of approximately 3,000 pounds per square inch (psi), a temperature of approximately 55 degrees Celsius and a flow rate of approximately 52 gm per minute. Using said conditions, the relatively low molecular weight cyclics and oligomers were removed from the silicone fluid to a level below size exclusion chromatography (SEC) detection limits. More particularly, SEC showed the removal of relatively low molecular weight cyclics and oligomers with no change in the silicone fluid peak height. Similar results were obtained by extracting with supercritical carbon dioxide fluid containing 10 percent acetone.
- The silicone oil tamponade purification process of the present invention is described in still greater detail in the examples that follow.
- Extraction of Silicone Oil with Supercritical Carbon Dioxide Fluid:
- Polydimethylsiloxane (21.01 gm) sample was loaded into a 0.7 inch tube. The loaded tube was then placed in a 3.0 inch cup. The 3.0 inch cup with the sample was placed into an extraction vessel and a lid with a ¼ inch pipe attachment was placed on the extraction vessel. The lid was placed such that the ¼ inch pipe attachment was inside the 0.7 inch tube. The extraction vessel was then pressurized to 140 bar with carbon dioxide using bottom to top flow. The extraction vessel temperature was approximately 55 degrees Celsius in an oil bath of approximately 102 degrees Celsius. A flow of 26 gm per minute carbon dioxide was begun in the extraction vessel from the top to the bottom. After one hour and 37 minutes, an increased flow rate of 52 gm per minute carbon dioxide was begun. After one hour and fifty-three minutes, the extraction vessel pressure was increased to 207 bar. After a total of four hours, the flow of carbon dioxide was discontinued and the extraction vessel was depressurized.
Initial weights: Extraction vessel = 231.46 gm Cup = 217.73 gm Lid and pipe = 339.64 gm Tube = 60.96 gm Sample = 21.01 gm -
TABLE 1 SCF Extraction Process Conditions Summary for Example 1: Initial Conditions: CO2 rate: approximately 55 gm/minute driven by cylinder pressure up to 55-60 bars Vessel pressure: 140 bars Vessel temperature: 55 degrees Celsius Oil bath temperature: 102 degrees Celsius Process Conditions: CO2 rate: approximately 26 gm/minute Vessel pressure: 140 bars Flow time: 90 minutes CO2 rate: approximately 52 gm/minute Vessel pressure: 140 bars Flow time: 16 minutes CO2 rate: approximately 52 gm/minute Vessel pressure: 207 bars Flow time: 67 minutes - Extraction of Silicone Oil with Supercritical Carbon Dioxide Fluid and Acetone:
- Polydimethylsiloxane (21.01 gm) sample was loaded into a 0.7 inch tube. The loaded tube was then placed in a 3.0 inch cup. The 3.0 inch cup with the sample was then placed in an extraction vessel and a lid with a ¼ inch pipe attachment was placed on the extraction vessel. The lid was placed such that the ¼ inch pipe attachment was inside the 0.7 inch tube. The extraction vessel was then pressurized to 140 bar with carbon dioxide using bottom to top flow. The extraction vessel temperature was approximately 55 degrees Celsius in an oil bath of approximately 102 degrees Celsius. A flow of 6 gm per minute acetone and 20 gm per minute carbon dioxide was begun in the extraction vessel from the top to the bottom. After one and a half hours, 404.5 gm of acetone had been used. The flow of acetone was then discontinued while the flow of carbon dioxide was continued for an additional two and a half hours. The flow of carbon dioxide was likewise then discontinued and the extraction vessel was depressurized.
TABLE 2 SCF Extraction Process Conditions Summary for Examnle 2: Initial Conditions: CO2 rate: approximately 55 gm/minute driven by cylinder pressure up to 55-60 bars Vessel pressure: 140 bars Vessel temperature: 55 degrees Celsius Oil bath temperature: 102 degrees Celsius Process Conditions: CO2 rate: approximately 20 gm/minute Acetone rate: 6 gm/minute Pumping time: 90 minutes Vessel pressure: 140 bars Drying Conditions: CO2 rate: approximately 20 gm/minute Acetone rate: 0 gm/minute Flow time: 150 minutes -
CHART 1 Comparative Results for Silicone Oil Extracted by Various Processes Viscosity at Surface 21° C. tension, Interfacial tension, Sample cps (mPa-s) dynes/cm (mN/m) dynes/cm (mN/m) Silicone oil 5,700 24.2 Could not be unextracted measured Acetone extracted 6,800 25.4 Difficult to measure silicone oil due to closeness of oil/water phase densities sc-CO2/ 6,890 25.4 30 with distinct acetone phases extracted silicone oil sc-CO2 8,000 25.4 32 with distinct extracted phases silicone oil - Silicone oil or fluid ocular tamponades purified using the purification process of the present invention are used as customary in the field of ophthalmology. For example, in a surgical vitreoretinal procedure, the silicone oil or fluid ocular tamponade purified in accordance with the process of the present invention is placed and maintained in the posterior segment of the eye for the desired period of time prior to the removal thereof.
- While there is shown and described herein a process for the purification of silicone oil or fluid for use as an ocular tamponade using supercritical carbon dioxide fluid or a supercritical carbon dioxide mixture fluid, it will be manifest to those skilled in the art that various modifications may be made without departing from the spirit and scope of the underlying inventive concept and that the same is not limited to particular processes herein described except insofar as indicated by the scope of the appended claims.
Claims (16)
1. A process for the purification of silicone oil or fluid for use as an ocular tamponade comprising:
performing a supercritical carbon dioxide extraction of said silicone oil or fluid to remove cyclic and oligomeric impurities.
2. A process for the purification of silicone oil or fluid for use as an ocular tamponade comprising:
performing a supercritical carbon dioxide mixture extraction of said silicone oil or fluid to remove cyclic and oligomeric impurities.
3. The process of claim 1 wherein said extraction is conducted at a pressure of approximately 3000 psi, a temperature of approximately 55 degrees Celsius and a carbon dioxide flow rate of approximately 52 gm/minute.
4. The process of claim 2 wherein said extraction is conducted at a pressure of approximately 3000 psi, a temperature of approximately 55 degrees Celsius and a carbon dioxide mixture flow rate of approximately 52 gm/minute.
5. The process of claim 1 wherein said extraction is conducted at a carbon dioxide flow rate of approximately 20 to 26 gm/minute and a flow time of approximately 90 minutes.
6. The process of claim 2 wherein said extraction is conducted at a carbon dioxide mixture flow rate of approximately 20 to 26 gm/minute and a flow time of approximately 90 minutes.
7. The process of claim 2 wherein said carbon dioxide mixture comprises approximately 90 percent carbon dioxide and approximately 10 percent acetone.
8. The process of claim 2 wherein said carbon dioxide mixture comprises carbon dioxide and a modifier.
9. The process of claim 2 wherein said carbon dioxide mixture comprises carbon dioxide and acetone or acetonitrile.
10. The process of claim 2 wherein said carbon dioxide mixture comprises carbon dioxide and methanol.
11. The process of claim 2 wherein said carbon dioxide mixture comprises carbon dioxide and isopropanol.
12. The process of claim 2 wherein said carbon dioxide mixture comprises approximately 90 percent carbon dioxide and approximately 10 percent methanol.
13. The process of claim 2 wherein said carbon dioxide mixture comprises approximately 90 percent carbon dioxide and approximately 10 percent isopropanol.
14. A silixone oil or fluid ophthalmic tamponade produced using the process of claim 1 or 2.
15. A method of using the silicone oil or fluid ophthalmic tamponade of claim 14 in an ophthalmic surgical procedure comprising:
creating an incision into a posterior chamber of an eye;
positioning damaged retinal tissue within the eye; and
filling said posterior chamber of the eye with said silicone oil.
16. A method of using the silicone oil ophthalmic tamponade of claim 14 in an ophthalmic surgical procedure comprising:
creating an incision into a posterior chamber of an eye; and
filling said posterior chamber of the eye with said silicone oil or fluid.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/165,834 US20030181749A1 (en) | 2002-03-21 | 2002-06-07 | Supercritical fluid extraction of vitreoretinal silicone tamponades |
DE60323471T DE60323471D1 (en) | 2002-03-21 | 2003-03-20 | EXTRACTION OF VITREORETINAL SILICONTAMPONADES WITH SUPERCRITICAL LIQUIDS |
ES03714340T ES2312759T3 (en) | 2002-03-21 | 2003-03-20 | EXTRACTION WITH SUPERCRITICAL FLUID OF VITREORETINAL SILICONE COUPLINGS. |
AU2003218343A AU2003218343A1 (en) | 2002-03-21 | 2003-03-20 | Supercritical fluid extraction of vitreoretinal silicone tamponades |
PCT/US2003/008902 WO2003080713A1 (en) | 2002-03-21 | 2003-03-20 | Supercritical fluid extraction of vitreoretinal silicone tamponades |
EP03714340A EP1487903B1 (en) | 2002-03-21 | 2003-03-20 | Supercritical fluid extraction of vitreoretinal silicone tamponades |
ARP030100992 AR039095A1 (en) | 2002-06-07 | 2003-03-21 | SUPERCRITICAL FLUID EXTRACTION OF VITREORETINAL SILICONE TAMPONS |
US10/801,741 US7276619B2 (en) | 2002-03-21 | 2004-03-16 | Vitreoretinal silicone tamponades made by supercritical fluid extraction |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36669602P | 2002-03-21 | 2002-03-21 | |
US10/165,834 US20030181749A1 (en) | 2002-03-21 | 2002-06-07 | Supercritical fluid extraction of vitreoretinal silicone tamponades |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/801,741 Division US7276619B2 (en) | 2002-03-21 | 2004-03-16 | Vitreoretinal silicone tamponades made by supercritical fluid extraction |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030181749A1 true US20030181749A1 (en) | 2003-09-25 |
Family
ID=28044368
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/165,834 Abandoned US20030181749A1 (en) | 2002-03-21 | 2002-06-07 | Supercritical fluid extraction of vitreoretinal silicone tamponades |
US10/801,741 Expired - Fee Related US7276619B2 (en) | 2002-03-21 | 2004-03-16 | Vitreoretinal silicone tamponades made by supercritical fluid extraction |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/801,741 Expired - Fee Related US7276619B2 (en) | 2002-03-21 | 2004-03-16 | Vitreoretinal silicone tamponades made by supercritical fluid extraction |
Country Status (6)
Country | Link |
---|---|
US (2) | US20030181749A1 (en) |
EP (1) | EP1487903B1 (en) |
AU (1) | AU2003218343A1 (en) |
DE (1) | DE60323471D1 (en) |
ES (1) | ES2312759T3 (en) |
WO (1) | WO2003080713A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013520291A (en) * | 2010-02-23 | 2013-06-06 | パワーヴィジョン・インコーポレーテッド | Liquid for accommodation type intraocular lens |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030060878A1 (en) * | 2001-08-31 | 2003-03-27 | Shadduck John H. | Intraocular lens system and method for power adjustment |
US8048155B2 (en) | 2002-02-02 | 2011-11-01 | Powervision, Inc. | Intraocular implant devices |
US7217288B2 (en) | 2002-12-12 | 2007-05-15 | Powervision, Inc. | Accommodating intraocular lens having peripherally actuated deflectable surface and method |
US10835373B2 (en) | 2002-12-12 | 2020-11-17 | Alcon Inc. | Accommodating intraocular lenses and methods of use |
US8328869B2 (en) | 2002-12-12 | 2012-12-11 | Powervision, Inc. | Accommodating intraocular lenses and methods of use |
US8361145B2 (en) | 2002-12-12 | 2013-01-29 | Powervision, Inc. | Accommodating intraocular lens system having circumferential haptic support and method |
CA2517576A1 (en) | 2003-03-06 | 2004-09-23 | John H. Shadduck | Adaptive optic lens and method of making |
US7368589B2 (en) * | 2003-10-31 | 2008-05-06 | Johnson & Johnson Vision Care, Inc. | Purification of silicone containing compounds by supercritical fluid extraction |
US9872763B2 (en) | 2004-10-22 | 2018-01-23 | Powervision, Inc. | Accommodating intraocular lenses |
KR101261390B1 (en) | 2005-04-06 | 2013-05-09 | 다우 코닝 코포레이션 | Organosiloxane compositions |
US8668734B2 (en) | 2010-07-09 | 2014-03-11 | Powervision, Inc. | Intraocular lens delivery devices and methods of use |
US8968396B2 (en) | 2007-07-23 | 2015-03-03 | Powervision, Inc. | Intraocular lens delivery systems and methods of use |
EP2178462B1 (en) | 2007-07-23 | 2014-04-02 | PowerVision, Inc. | Post-implant lens power modification |
JP5346022B2 (en) | 2007-07-23 | 2013-11-20 | パワーヴィジョン・インコーポレーテッド | Accommodating intraocular lens and method of use |
WO2009015240A2 (en) | 2007-07-23 | 2009-01-29 | Powervision, Inc. | Lens delivery system |
US8314927B2 (en) | 2007-07-23 | 2012-11-20 | Powervision, Inc. | Systems and methods for testing intraocular lenses |
US10299913B2 (en) | 2009-01-09 | 2019-05-28 | Powervision, Inc. | Accommodating intraocular lenses and methods of use |
GB0905205D0 (en) | 2009-03-26 | 2009-05-13 | Dow Corning | Preparation of organosiloxane polymer |
GB0905204D0 (en) | 2009-03-26 | 2009-05-13 | Dow Corning | Preparation of organosiloxane polymers |
EP2473138A4 (en) * | 2009-08-31 | 2017-08-16 | PowerVision, Inc. | Lens capsule size estimation |
EP2563275A4 (en) | 2010-04-27 | 2017-11-22 | Lensgen, Inc | Accommodating intraocular lens device |
JP6071995B2 (en) | 2011-03-24 | 2017-02-01 | パワーヴィジョン・インコーポレーテッド | Intraocular lens loading system and method of use |
US10433949B2 (en) | 2011-11-08 | 2019-10-08 | Powervision, Inc. | Accommodating intraocular lenses |
EP3785668A1 (en) | 2013-03-15 | 2021-03-03 | Alcon Inc. | Intraocular lens storage and loading devices and methods of use |
CN106413634B (en) | 2013-11-01 | 2019-03-05 | 雷恩斯根公司 | Double component modulability intraocular lens equipment |
WO2015066502A1 (en) | 2013-11-01 | 2015-05-07 | Thomas Silvestrini | Accomodating intraocular lens device |
US10004596B2 (en) | 2014-07-31 | 2018-06-26 | Lensgen, Inc. | Accommodating intraocular lens device |
US10647831B2 (en) | 2014-09-23 | 2020-05-12 | LensGens, Inc. | Polymeric material for accommodating intraocular lenses |
AU2016275073B2 (en) | 2015-06-10 | 2021-02-25 | Alcon Inc. | Intraocular lens materials and components |
EP3884905A1 (en) | 2015-11-06 | 2021-09-29 | Alcon Inc. | Ccommodating intraocular lenses |
AU2016362384B2 (en) | 2015-12-01 | 2021-10-07 | Lensgen, Inc. | Accommodating intraocular lens device |
WO2017205811A1 (en) * | 2016-05-27 | 2017-11-30 | Thomas Silvestrini | Lens oil having a narrow molecular weight distribution for intraocular lens devices |
AU2020360242A1 (en) | 2019-10-04 | 2022-04-28 | Alcon Inc. | Adjustable intraocular lenses and methods of post-operatively adjusting intraocular lenses |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5340614A (en) * | 1993-02-11 | 1994-08-23 | Minnesota Mining And Manufacturing Company | Methods of polymer impregnation |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02302437A (en) * | 1989-05-17 | 1990-12-14 | Shin Etsu Chem Co Ltd | Method for purifying polyorganosilsesquioxane polymer |
JPH03202102A (en) * | 1989-12-28 | 1991-09-03 | Toray Dow Corning Silicone Co Ltd | Method for reducing amount of siloxane oligomer in organopolysiloxane molded product |
JPH06107796A (en) * | 1991-08-01 | 1994-04-19 | Chlorine Eng Corp Ltd | Purification of modified silicone oil |
JPH0543699A (en) * | 1991-08-15 | 1993-02-23 | Chlorine Eng Corp Ltd | Method for purifying silicone oil |
DE4220882C2 (en) * | 1992-06-25 | 1995-10-12 | Adatomed Pharma Chiron | Use of liquid perfluorocarbons for vitreous tamponade |
US5336487A (en) * | 1993-03-05 | 1994-08-09 | Refojo Miguel F | Method of treating eye disorders with silicon/fluorosilicone copolymer oil |
BR9507054A (en) * | 1994-01-31 | 1997-09-16 | Bausch & Lomb | Method for producing an optically transparent lens |
JPH09150002A (en) * | 1995-11-29 | 1997-06-10 | Shin Etsu Chem Co Ltd | Refining method for silicone oil |
ID18055A (en) | 1996-08-21 | 1998-02-26 | Novartis Ag | METHOD FOR TREATING MOLD GOODS |
US6228394B1 (en) * | 1997-10-14 | 2001-05-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Supercritical fluid extraction of mould lubricant from hard shell capsules |
US6294194B1 (en) * | 1997-10-14 | 2001-09-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for extraction and reaction using supercritical fluids |
-
2002
- 2002-06-07 US US10/165,834 patent/US20030181749A1/en not_active Abandoned
-
2003
- 2003-03-20 ES ES03714340T patent/ES2312759T3/en not_active Expired - Lifetime
- 2003-03-20 EP EP03714340A patent/EP1487903B1/en not_active Expired - Lifetime
- 2003-03-20 AU AU2003218343A patent/AU2003218343A1/en not_active Abandoned
- 2003-03-20 DE DE60323471T patent/DE60323471D1/en not_active Expired - Lifetime
- 2003-03-20 WO PCT/US2003/008902 patent/WO2003080713A1/en not_active Application Discontinuation
-
2004
- 2004-03-16 US US10/801,741 patent/US7276619B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5340614A (en) * | 1993-02-11 | 1994-08-23 | Minnesota Mining And Manufacturing Company | Methods of polymer impregnation |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013520291A (en) * | 2010-02-23 | 2013-06-06 | パワーヴィジョン・インコーポレーテッド | Liquid for accommodation type intraocular lens |
Also Published As
Publication number | Publication date |
---|---|
EP1487903B1 (en) | 2008-09-10 |
WO2003080713A1 (en) | 2003-10-02 |
US7276619B2 (en) | 2007-10-02 |
EP1487903A1 (en) | 2004-12-22 |
US20040176628A1 (en) | 2004-09-09 |
DE60323471D1 (en) | 2008-10-23 |
AU2003218343A1 (en) | 2003-10-08 |
ES2312759T3 (en) | 2009-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7276619B2 (en) | Vitreoretinal silicone tamponades made by supercritical fluid extraction | |
US6368359B1 (en) | Process for stabilization of dry cleaning solutions | |
JPH03202102A (en) | Method for reducing amount of siloxane oligomer in organopolysiloxane molded product | |
KR20030067478A (en) | Methods for extraction and reaction using supercritical fluids | |
KR970701749A (en) | PROCESS FOR INCREASING THE MOLECULAR WEIGHT OF POLYAMIDES AND OTHER CONDENSATION POLYMERS | |
KR101584727B1 (en) | Manufacturing method of high purity 1,2-hexanediol | |
CN113698606A (en) | Preparation method of vinyl silicone oil with low content of cyclic bodies | |
CN115612104B (en) | Production process of electronic grade 107 with low ring body content | |
US5312947A (en) | Siloxane purification | |
CN110358090A (en) | A kind of method for preparing polysiloxane by catalysis of supported phosphazene catalyst | |
WO2004026320A1 (en) | Vitreoretinal tamponades based on fluorosilicone fluids | |
JPH0674296B2 (en) | Rubber purification method | |
EP3974044A1 (en) | Process for the aqueous extraction of biosurfactants from corn steep liquor | |
CN105542171B (en) | A kind of alcohol-soluble lubricant and preparation method thereof | |
WO2015031085A1 (en) | Catalyst for synthesis of siloxanes | |
CA2378321A1 (en) | Molding of a polyalkylene glycol terephtalate and an aromatic ester | |
US20020000009A1 (en) | Process for stabilization of dry cleaning solutions | |
JP3622264B2 (en) | Method for stabilizing N-vinylamide | |
JPH06279401A (en) | Method of purifying n-methyl-2-pyrrolidone | |
CN114768284A (en) | Purification method of silicone oil for intraocular tamponade | |
RU2184729C1 (en) | Method of removing organic impurities from tocopherol prepared by chemical synthesis | |
KR970010947A (en) | Freezing point cooling process plum wine manufacturing method | |
RU2085147C1 (en) | Material for filling eye retina | |
TWI549994B (en) | A crossed siloxane macromolecule comprising polymerization functional groups and hydrophilic groups and method for manufacturing the crossed siloxane macromolecule | |
JPH01129022A (en) | Reduction of cyclic oligomer ether content in tetrahydrofuran copolymer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BAUSCH & LOMB INCORPORATED, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KUNZLER, JAY E.;SALAMONE, JOSEPH C.;JANI, DHARMENDRA;AND OTHERS;REEL/FRAME:013192/0774 Effective date: 20020625 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |